{"entity":{"id":"jonathan-ledermann","kind":"person","name":"Jonathan A. Ledermann","aka":[],"tldr":"Led Study 19, the trial that first showed PARP inhibitor maintenance works in ovarian cancer.","summary":"Jonathan Ledermann led Study 19, the randomised trial showing maintenance olaparib prolongs progression-free survival in platinum-sensitive relapsed ovarian cancer with the largest effect in BRCA-mutant disease, the proof of concept for every subsequent PARP inhibitor maintenance approval. He has led the ICON trials, chaired the Gynecologic Cancer InterGroup, and led ESMO-ESGO ovarian cancer guidelines.","asOf":"2026-09-10","links":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Ledermann%20JA%5BAuthor%5D%20ovarian%20olaparib"}],"tags":["ovarian","parp","uk"],"related":[],"cancers":["ovarian"],"sections":[],"technologies":["parp-inhibitor"],"targets":["parp","brca"],"drugs":["olaparib"],"companies":[],"institutions":["uclh"],"pathways":[],"terms":[],"trials":["gog-0218-icon7"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"role":"Professor of Medical Oncology, UCL Cancer Institute; Consultant, UCLH","institutionId":"uclh","specialisms":["Ovarian cancer","PARP inhibitors","Cooperative-group trials","Guidelines"],"profiles":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Ledermann%20JA%5BAuthor%5D%20ovarian%20olaparib"}],"papers":[{"title":"Olaparib maintenance therapy in platinum-sensitive relapsed ovarian cancer (Study 19)","journal":"NEJM","year":2012,"doi":"10.1056/NEJMoa1105535"},{"title":"Olaparib maintenance therapy in patients with platinum-sensitive relapsed serous ovarian cancer: a preplanned retrospective analysis of outcomes by BRCA status in a randomised phase 2 trial","journal":"Lancet Oncology","year":2014,"doi":"10.1016/S1470-2045(14)70228-1"}],"orcid":"0000-0003-3799-3539"},"route":"/people/jonathan-ledermann/","neighbours":{"cancer":[{"id":"ovarian","kind":"cancer","name":"Ovarian cancer","route":"/cancers/ovarian/"}],"technology":[{"id":"parp-inhibitor","kind":"technology","name":"PARP inhibitors","route":"/technologies/parp-inhibitor/"}],"target":[{"id":"brca","kind":"target","name":"BRCA1 / BRCA2 (HRD)","route":"/targets/brca/"},{"id":"parp","kind":"target","name":"PARP","route":"/targets/parp/"}],"drug":[{"id":"olaparib","kind":"drug","name":"Olaparib","route":"/drugs/olaparib/"}],"institution":[{"id":"uclh","kind":"institution","name":"University College London Hospitals / UCL Cancer Institute","route":"/institutions/uclh/"}],"trial":[{"id":"gog-0218-icon7","kind":"trial","name":"GOG-0218 & ICON7 (bevacizumab)","route":"/trials/gog-0218-icon7/"}]}}